skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8838

Anticonvulsant treatments of dysphoric mania: a trial of gabapentin, lamotrigine and carbamazepine in Iran

Original Research

(2539) Views  (811) Full article downloads

Authors: Naghmeh Mokhber, Carol J Lane, Mohamad R Azarpazhooh, Elham Salari, Reza Fayazi, et al

Published Date May 2008 Volume 2008:4(1) Pages 227 - 234
DOI: http://dx.doi.org/10.2147/NDT.S2316

Naghmeh Mokhber1, Carol J Lane2, Mohamad R Azarpazhooh3, Elham Salari4, Reza Fayazi5, Mohamad T Shakeri6, Allan H Young7

1Assistant Professor of Psychiatry, 3Assistant Professor of Neurology, 4Mashhad Department of Forensic Psychiatry, 5Assistant Professor of Psychiatry, 6Assistant Professor of Statistics, Mashhad University of Medical Science, Mashhad, Iran; 2Department of Psychiatry, University of British Columbia, Vancouver, Canada7

Abstract: The treatment of dysphoric mania is challenging given the need to treat symptoms of both depression and mania simultaneously without provoking any clinical exacerbation. The newer antiepileptic drugs such as gabapentin, lamotrogine, and carbamazepine are often used as adjuncts to either lithium or valproic acid in the treatment of bipolar disorder. We decided to undertake a monotherapy trial because previous evidence suggested mixed states may be more responsive to anticonvulsants than more traditional antimanic agents. 51 patients with a DSM IV diagnosis of dysphoric mania were randomized to three groups comprising gapbapentin, lamotrogine or carbamazepine and followed for 8 weeks. Psychiatric diagnosis was verified by the structural clinical interview for the DSM-IV (SCID). The MMPI-2 in full was used to assess symptoms at baseline and 8 weeks. All three groups showed significant changes in MMPI-2 scores for depression and mania subscales. Gabapentin showed the greatest change in depression symptom improvement relative to lamotrogine and carbamazepine, respectively. Although manic symptoms improved overall, there were no differences between groups in the degree of manic symptom improvement.

Keywords: dysphoric mania, manic-depression, depression, anticonvulsant, mood stabilizer








Readers of this article also read:

Treatment of adult ADHD: Is current knowledge useful to clinicians?
Neurosteroids block the increase in intracellular calcium level induced by Alzheimer’s β-amyloid protein in long-term cultured rat hippocampal neurons
Neuroprotection of lamotrigine on hypoxic-ischemic brain damage in neonatal rats: Relations to administration time and doses
Mycophenolate mofetil for myasthenia gravis: a clear and present controversy
Treatment of Lennox-Gastaut syndrome: overview and recent findings
Current trends in the treatment of infantile spasms
Efficacy, safety, and potential of extended-release lamotrigine in the treatment of epileptic patients
Adjunctive therapy for the treatment of primary generalized tonic-clonic seizures: focus on once-daily lamotrigine
A systematic writing program as a tool in the grief process: part 1
A descriptive analysis of drug treatment patterns and burden of illness for pediatric patients diagnosed with partial-onset seizures in the USA